Bristol Myers Squibb & Co (NYSE:BMY) posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 ...

Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...

Increases in the sales of drugs from the growth portfolio and Eliquis were offset by the generic erosion of Sprycel Revlimid, Abraxane and Pomalyst. BMY’s Growth Portfolio comprises ...

Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Shares of The Bristol-Myers Squibb Company (NYSE: BMY)are attempting to claw their way back into positive territory after the ...

While reporting financial results for the fourth quarter on Thursday, Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings ...

The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...